347 related articles for article (PubMed ID: 21240620)
1. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up.
Tochimoto A; Kawaguchi Y; Hara M; Tateishi M; Fukasawa C; Takagi K; Nishimagi E; Ota Y; Katsumata Y; Gono T; Tanaka E; Yamanaka H
Mod Rheumatol; 2011 Jun; 21(3):296-301. PubMed ID: 21240620
[TBL] [Abstract][Full Text] [Related]
2. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
3. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis.
Masui Y; Asano Y; Takahashi T; Shibata S; Akamata K; Aozasa N; Noda S; Taniguchi T; Ichimura Y; Toyama T; Tamaki Z; Sumida H; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
Mod Rheumatol; 2013 Mar; 23(2):323-9. PubMed ID: 22610787
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis.
Takahashi T; Asano Y; Akamata K; Aozasa N; Taniguchi T; Noda S; Masui Y; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
Mod Rheumatol; 2013 Sep; 23(5):884-90. PubMed ID: 22972016
[TBL] [Abstract][Full Text] [Related]
6. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.
Vanthuyne M; Blockmans D; Westhovens R; Roufosse F; Cogan E; Coche E; Nzeusseu Toukap A; Depresseux G; Houssiau FA
Clin Exp Rheumatol; 2007; 25(2):287-92. PubMed ID: 17543155
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG
J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824
[TBL] [Abstract][Full Text] [Related]
9. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
10. Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis?
Pérez Campos D; Estévez Del Toro M; Peña Casanovas A; González Rojas PP; Morales Sánchez L; Gutiérrez Rojas AR
Reumatol Clin; 2012; 8(2):58-62. PubMed ID: 22317852
[TBL] [Abstract][Full Text] [Related]
11. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.
Saigusa R; Asano Y; Nakamura K; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Yoshizaki A; Miyazaki M; Tamaki Z; Sato S
Mod Rheumatol; 2017 Jul; 27(4):618-622. PubMed ID: 27538472
[TBL] [Abstract][Full Text] [Related]
12. Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: An Open-Label Study.
Kundu S; Paul S; Hariprasath K; Agarwal R; Ghosh S; Biswas D
Indian J Chest Dis Allied Sci; 2016; 58(1):7-10. PubMed ID: 28368564
[TBL] [Abstract][Full Text] [Related]
13. Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases.
Takahashi T; Asano Y; Amiya E; Hatano M; Tamaki Z; Ozeki A; Watanabe A; Kawarasaki S; Nakao T; Taniguchi T; Ichimura Y; Toyama T; Watanabe M; Hirata Y; Nagai R; Sato S
Mod Rheumatol; 2012 Aug; 22(4):598-601. PubMed ID: 22015621
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
16. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases.
Schnabel A; Reuter M; Gross WL
Arthritis Rheum; 1998 Jul; 41(7):1215-20. PubMed ID: 9663478
[TBL] [Abstract][Full Text] [Related]
17. [Interstitial lung disease in systemic sclerosis].
Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
[TBL] [Abstract][Full Text] [Related]
18. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
19. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic options for systemic sclerosis related interstitial lung diseases.
Mouthon L; Bérezné A; Guillevin L; Valeyre D
Respir Med; 2010 Jul; 104 Suppl 1():S59-69. PubMed ID: 20630349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
